Tabauac, Leny M.
HRN: 22-28-04 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/30/2022
12/02/2022
IVT
500mg
Q8
Thickly MSAF
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes